% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Sergeeva:852453,
author = {Sergeeva, Olga A. and De Luca, Roberto and Mazur, Karolina
and Chepkova, Aissa N. and Haas, Helmut L. and Bauer,
Andreas},
title = {{N}-oleoyldopamine modulates activity of midbrain
dopaminergic neurons through multiple mechanisms},
journal = {Neuropharmacology},
volume = {119},
issn = {0028-3908},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {FZJ-2018-05399},
pages = {111 - 122},
year = {2017},
abstract = {N-oleoyl-dopamine (OLDA) is an amide of dopamine and oleic
acid, synthesized in catecholaminergic neurons. The present
study investigates OLDA targets in midbrain dopaminergic
(DA) neurons. Substantia Nigra compacta (SNc) DA neurons
recorded in brain slices were excited by OLDA in wild type
mice. In transient receptor potential vanilloid 1 (TRPV1)
knockout (KO) mice, however, SNc DA neurons displayed
sustained inhibition of firing. In the presence of the
dopamine type 2 receptor (D2R) antagonist sulpiride or the
dopamine transporter blocker nomifensine no such inhibition
was observed. Under sulpiride OLDA slightly excited SNc DA
neurons, an action abolished upon combined application of
the cannabinoid1 and 2 receptor antagonists AM251 and AM630.
In ventral tegmental area (VTA) DA neurons from TRPV1 KO
mice a transient inhibition of firing by OLDA was observed.
Thus OLDA modulates the firing of nigrostriatal DA neurons
through interactions with TRPV1, cannabinoid receptors and
dopamine uptake. These findings suggest further development
of OLDA-like tandem molecules for the treatment of movement
disorders including Parkinson's disease.},
cin = {INM-2},
ddc = {610},
cid = {I:(DE-Juel1)INM-2-20090406},
pnm = {573 - Neuroimaging (POF3-573) / 571 - Connectivity and
Activity (POF3-571)},
pid = {G:(DE-HGF)POF3-573 / G:(DE-HGF)POF3-571},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:28400256},
UT = {WOS:000403513800010},
doi = {10.1016/j.neuropharm.2017.04.011},
url = {https://juser.fz-juelich.de/record/852453},
}